PittsburghV1, Ncbi, Merge, bibRecord, 004209

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

Identifieur interne : 004209 ( Ncbi/Merge ); précédent : 004208; suivant : 004210

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

Auteurs : Victoria Plamadeala [États-Unis] ; Joseph L. Kelley [États-Unis] ; John K. Chan [États-Unis] ; Thomas C. Krivak [États-Unis] ; Michael J. Gabrin [États-Unis] ; Stacey L. Brower [États-Unis] ; Matthew A. Powell [États-Unis] ; Thomas J. Rutherford [États-Unis] ; Robert L. Coleman [États-Unis]

Source :

Gynecologic oncology [ 1095-6859 ] ; 2015.

RBID : pubmed:25462203

Descripteurs français

English descriptors

KwdEn :
- Cohort Studies, Cost-Benefit Analysis, Drug Resistance, Neoplasm, Female, Gynecologic Surgical Procedures (economics), Humans, Markov Chains, Models, Economic, Neoplasm Recurrence, Local (drug therapy), Neoplasm Recurrence, Local (economics), Neoplasm Recurrence, Local (surgery), Neoplasms, Glandular and Epithelial (drug therapy), Neoplasms, Glandular and Epithelial (economics), Neoplasms, Glandular and Epithelial (surgery), Organoplatinum Compounds (administration & dosage), Organoplatinum Compounds (adverse effects), Organoplatinum Compounds (economics), Ovarian Neoplasms (drug therapy), Ovarian Neoplasms (economics), Ovarian Neoplasms (surgery), Proportional Hazards Models, Survival Rate, United States.
MESH :
- chemical , administration & dosage : Organoplatinum Compounds.
- chemical , adverse effects : Organoplatinum Compounds.
- geographic : United States.
- drug therapy : Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms.
- economics : Gynecologic Surgical Procedures, Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Organoplatinum Compounds, Ovarian Neoplasms.
- surgery : Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms.
- Cohort Studies, Cost-Benefit Analysis, Drug Resistance, Neoplasm, Female, Humans, Markov Chains, Models, Economic, Proportional Hazards Models, Survival Rate.

Abstract

Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective.

DOI: 10.1016/j.ygyno.2014.11.019
PubMed: 25462203

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000818
to stream PubMed, to step Curation: 000818
to stream PubMed, to step Checkpoint: 000818

Links to Exploration step

pubmed:25462203

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.</title>
<author><name sortKey="Plamadeala, Victoria" sort="Plamadeala, Victoria" uniqKey="Plamadeala V" first="Victoria" last="Plamadeala">Victoria Plamadeala</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kelley, Joseph L" sort="Kelley, Joseph L" uniqKey="Kelley J" first="Joseph L" last="Kelley">Joseph L. Kelley</name>
<affiliation wicri:level="2"><nlm:affiliation>Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Magee-Womens Hospital of UPMC, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name>
<affiliation wicri:level="2"><nlm:affiliation>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krivak, Thomas C" sort="Krivak, Thomas C" uniqKey="Krivak T" first="Thomas C" last="Krivak">Thomas C. Krivak</name>
<affiliation wicri:level="2"><nlm:affiliation>The Western Pennsylvania Hospital, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Western Pennsylvania Hospital, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gabrin, Michael J" sort="Gabrin, Michael J" uniqKey="Gabrin M" first="Michael J" last="Gabrin">Michael J. Gabrin</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brower, Stacey L" sort="Brower, Stacey L" uniqKey="Brower S" first="Stacey L" last="Brower">Stacey L. Brower</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States. Electronic address: sbrower@helomics.com.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Powell, Matthew A" sort="Powell, Matthew A" uniqKey="Powell M" first="Matthew A" last="Powell">Matthew A. Powell</name>
<affiliation wicri:level="4"><nlm:affiliation>Washington University School of Medicine, St. Louis, MO, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Washington University School of Medicine, St. Louis, MO</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Rutherford, Thomas J" sort="Rutherford, Thomas J" uniqKey="Rutherford T" first="Thomas J" last="Rutherford">Thomas J. Rutherford</name>
<affiliation wicri:level="2"><nlm:affiliation>Yale University School of Medicine, New Haven, CT, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Yale University School of Medicine, New Haven, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25462203</idno>
<idno type="pmid">25462203</idno>
<idno type="doi">10.1016/j.ygyno.2014.11.019</idno>
<idno type="wicri:Area/PubMed/Corpus">000818</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000818</idno>
<idno type="wicri:Area/PubMed/Curation">000818</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000818</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000818</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000818</idno>
<idno type="wicri:Area/Ncbi/Merge">004209</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.</title>
<author><name sortKey="Plamadeala, Victoria" sort="Plamadeala, Victoria" uniqKey="Plamadeala V" first="Victoria" last="Plamadeala">Victoria Plamadeala</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kelley, Joseph L" sort="Kelley, Joseph L" uniqKey="Kelley J" first="Joseph L" last="Kelley">Joseph L. Kelley</name>
<affiliation wicri:level="2"><nlm:affiliation>Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Magee-Womens Hospital of UPMC, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name>
<affiliation wicri:level="2"><nlm:affiliation>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krivak, Thomas C" sort="Krivak, Thomas C" uniqKey="Krivak T" first="Thomas C" last="Krivak">Thomas C. Krivak</name>
<affiliation wicri:level="2"><nlm:affiliation>The Western Pennsylvania Hospital, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Western Pennsylvania Hospital, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gabrin, Michael J" sort="Gabrin, Michael J" uniqKey="Gabrin M" first="Michael J" last="Gabrin">Michael J. Gabrin</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brower, Stacey L" sort="Brower, Stacey L" uniqKey="Brower S" first="Stacey L" last="Brower">Stacey L. Brower</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States. Electronic address: sbrower@helomics.com.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Powell, Matthew A" sort="Powell, Matthew A" uniqKey="Powell M" first="Matthew A" last="Powell">Matthew A. Powell</name>
<affiliation wicri:level="4"><nlm:affiliation>Washington University School of Medicine, St. Louis, MO, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Washington University School of Medicine, St. Louis, MO</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Rutherford, Thomas J" sort="Rutherford, Thomas J" uniqKey="Rutherford T" first="Thomas J" last="Rutherford">Thomas J. Rutherford</name>
<affiliation wicri:level="2"><nlm:affiliation>Yale University School of Medicine, New Haven, CT, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Yale University School of Medicine, New Haven, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Gynecologic oncology</title>
<idno type="eISSN">1095-6859</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cohort Studies</term>
<term>Cost-Benefit Analysis</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Gynecologic Surgical Procedures (economics)</term>
<term>Humans</term>
<term>Markov Chains</term>
<term>Models, Economic</term>
<term>Neoplasm Recurrence, Local (drug therapy)</term>
<term>Neoplasm Recurrence, Local (economics)</term>
<term>Neoplasm Recurrence, Local (surgery)</term>
<term>Neoplasms, Glandular and Epithelial (drug therapy)</term>
<term>Neoplasms, Glandular and Epithelial (economics)</term>
<term>Neoplasms, Glandular and Epithelial (surgery)</term>
<term>Organoplatinum Compounds (administration & dosage)</term>
<term>Organoplatinum Compounds (adverse effects)</term>
<term>Organoplatinum Compounds (economics)</term>
<term>Ovarian Neoplasms (drug therapy)</term>
<term>Ovarian Neoplasms (economics)</term>
<term>Ovarian Neoplasms (surgery)</term>
<term>Proportional Hazards Models</term>
<term>Survival Rate</term>
<term>United States</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term>
<term>Chaines de Markov</term>
<term>Composés organiques du platine (administration et posologie)</term>
<term>Composés organiques du platine (effets indésirables)</term>
<term>Composés organiques du platine (économie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Modèles économiques</term>
<term>Procédures de chirurgie gynécologique (économie)</term>
<term>Récidive tumorale locale ()</term>
<term>Récidive tumorale locale (traitement médicamenteux)</term>
<term>Récidive tumorale locale (économie)</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Taux de survie</term>
<term>Tumeurs de l'ovaire ()</term>
<term>Tumeurs de l'ovaire (traitement médicamenteux)</term>
<term>Tumeurs de l'ovaire (économie)</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires ()</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires (traitement médicamenteux)</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires (économie)</term>
<term>États-Unis d'Amérique</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Organoplatinum Compounds</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Organoplatinum Compounds</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Composés organiques du platine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasm Recurrence, Local</term>
<term>Neoplasms, Glandular and Epithelial</term>
<term>Ovarian Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Gynecologic Surgical Procedures</term>
<term>Neoplasm Recurrence, Local</term>
<term>Neoplasms, Glandular and Epithelial</term>
<term>Organoplatinum Compounds</term>
<term>Ovarian Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Composés organiques du platine</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Neoplasm Recurrence, Local</term>
<term>Neoplasms, Glandular and Epithelial</term>
<term>Ovarian Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Récidive tumorale locale</term>
<term>Tumeurs de l'ovaire</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Composés organiques du platine</term>
<term>Procédures de chirurgie gynécologique</term>
<term>Récidive tumorale locale</term>
<term>Tumeurs de l'ovaire</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cohort Studies</term>
<term>Cost-Benefit Analysis</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Humans</term>
<term>Markov Chains</term>
<term>Models, Economic</term>
<term>Proportional Hazards Models</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term>
<term>Chaines de Markov</term>
<term>Femelle</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Modèles économiques</term>
<term>Récidive tumorale locale</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Taux de survie</term>
<term>Tumeurs de l'ovaire</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires</term>
<term>États-Unis d'Amérique</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25462203</PMID>
<DateCreated><Year>2015</Year>
<Month>01</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>03</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-6859</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>136</Volume>
<Issue>1</Issue>
<PubDate><Year>2015</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Gynecologic oncology</Title>
<ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.</ArticleTitle>
<Pagination><MedlinePgn>94-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2014.11.019</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0090-8258(14)01484-X</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Using a Markov state transition model, patient characteristics and survival data from the recent clinical study, the cumulative costs over the study horizon (71 months) for both the baseline (no assay) and intervention (assay consistent, hypothetical) cohorts were evaluated.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The assay consistent cohort had an incremental cost effectiveness ratio (ICER) of $6206 per life year saved (LYS), as compared to the baseline cohort. Cost-effectiveness was further demonstrated in platinum-sensitive and platinum-resistant populations treated with assay-sensitive therapies, with ICERs of $2773 per LYS and $2736 per LYS, respectively.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of a chemoresponse assay to inform treatment decisions in recurrent ovarian cancer patients has the potential to be cost-effective in both platinum-sensitive and platinum-resistant patients.</AbstractText>
<CopyrightInformation>Copyright © 2014. Published by Elsevier Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plamadeala</LastName>
<ForeName>Victoria</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kelley</LastName>
<ForeName>Joseph L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo><Affiliation>Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>John K</ForeName>
<Initials>JK</Initials>
<AffiliationInfo><Affiliation>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Krivak</LastName>
<ForeName>Thomas C</ForeName>
<Initials>TC</Initials>
<AffiliationInfo><Affiliation>The Western Pennsylvania Hospital, Pittsburgh, PA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gabrin</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brower</LastName>
<ForeName>Stacey L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo><Affiliation>Helomics™ Corporation, Pittsburgh, PA, United States. Electronic address: sbrower@helomics.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Powell</LastName>
<ForeName>Matthew A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rutherford</LastName>
<ForeName>Thomas J</ForeName>
<Initials>TJ</Initials>
<AffiliationInfo><Affiliation>Yale University School of Medicine, New Haven, CT, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Coleman</LastName>
<ForeName>Robert L</ForeName>
<Initials>RL</Initials>
<AffiliationInfo><Affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, United States.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>11</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Gynecol Oncol</MedlineTA>
<NlmUniqueID>0365304</NlmUniqueID>
<ISSNLinking>0090-8258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C538090">Ovarian epithelial cancer</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013509" MajorTopicYN="N">Gynecologic Surgical Procedures</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008390" MajorTopicYN="N">Markov Chains</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemoresponse assay</Keyword>
<Keyword MajorTopicYN="N">Chemotherapy sensitivity and resistance assay (CSRA)</Keyword>
<Keyword MajorTopicYN="N">Cost-effectiveness</Keyword>
<Keyword MajorTopicYN="N">Markov transition model</Keyword>
<Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>08</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>12</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>12</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>3</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25462203</ArticleId>
<ArticleId IdType="pii">S0090-8258(14)01484-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.ygyno.2014.11.019</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Connecticut</li>
<li>Missouri (État)</li>
<li>Pennsylvanie</li>
<li>Texas</li>
</region>
<settlement><li>Saint-Louis (Missouri)</li>
</settlement>
<orgName><li>École de médecine (Université Washington de Saint-Louis)</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Plamadeala, Victoria" sort="Plamadeala, Victoria" uniqKey="Plamadeala V" first="Victoria" last="Plamadeala">Victoria Plamadeala</name>
</region>
<name sortKey="Brower, Stacey L" sort="Brower, Stacey L" uniqKey="Brower S" first="Stacey L" last="Brower">Stacey L. Brower</name>
<name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name>
<name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name>
<name sortKey="Gabrin, Michael J" sort="Gabrin, Michael J" uniqKey="Gabrin M" first="Michael J" last="Gabrin">Michael J. Gabrin</name>
<name sortKey="Kelley, Joseph L" sort="Kelley, Joseph L" uniqKey="Kelley J" first="Joseph L" last="Kelley">Joseph L. Kelley</name>
<name sortKey="Krivak, Thomas C" sort="Krivak, Thomas C" uniqKey="Krivak T" first="Thomas C" last="Krivak">Thomas C. Krivak</name>
<name sortKey="Powell, Matthew A" sort="Powell, Matthew A" uniqKey="Powell M" first="Matthew A" last="Powell">Matthew A. Powell</name>
<name sortKey="Rutherford, Thomas J" sort="Rutherford, Thomas J" uniqKey="Rutherford T" first="Thomas J" last="Rutherford">Thomas J. Rutherford</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004209 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004209 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:25462203
   |texte=   A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:25462203" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki